Findings of Scientific Misconduct, 55848 [E9-26007]

Download as PDF 55848 Federal Register / Vol. 74, No. 208 / Thursday, October 29, 2009 / Notices representation is true and substantiated. Part III of the proposed order prohibits respondents from failing to comply with the Textile Act or the Textile Rules. Parts IV through VIII require respondents to keep copies of relevant advertisements and materials substantiating claims made in the advertisements; to provide copies of the order to certain of their personnel; to notify the Commission of changes in corporate structure that might affect compliance obligations under the order; to notify the Commission of changes in the individual respondents’ current business or employment; and to file compliance reports with the Commission and respond to other requests from FTC staff. Part IX provides that the order will terminate after twenty (20) years under certain circumstances. The purpose of this analysis is to facilitate public comment on the proposed order. It is not intended to constitute an official interpretation of the agreement and proposed order or to modify in any way its terms. By direction of the Commission. Donald S. Clark Secretary. [FR Doc. E9–26006 Filed 10–28–09: 8:45 am] BILLING CODE 6750–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Scientific Misconduct Office of the Secretary, HHS. Notice. AGENCY: ACTION: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case: Zhong Bin Deng, Medical College of Georgia: Based on the report of an investigation conducted by the Medical College of Georgia (MCG), the report of the MCG Adjudication Subcommittee, additional analysis conducted by ORI in its oversight review, and the Respondent’s written and oral admissions and expressed remorse, ORI found that Dr. Zhong Bin Deng, former postdoctoral fellow at MCG in Augusta, GA, engaged in scientific misconduct in research supported by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), grant 2 P01 AI42288. ORI found that Dr. Deng engaged in scientific/research misconduct by falsifying research results reported in a dcolon on DSK2BSOYB1PROD with NOTICES SUMMARY: VerDate Nov<24>2008 17:02 Oct 28, 2009 Jkt 220001 paper published in Nature Medicine.1 Specifically: • Figures 1 and 2 in the Nature Medicine paper purportedly show that the autoimmune regulator Arie controls iNKT cell development and maturation. In Figure 1(a), the Respondent falsified the Aire +/+ (thymus and liver) flow cytometry plots by substituting Aire +/ ¥ (thymus and liver) flow cytometry plots that were altered to disguise their origins and falsified the Aire ¥/¥ (bone marrow) flow cytometry plot by substituting the Aire +/¥ (bone marrow) flow cytometry plot, also altered to disguise its origin. • In supplementary Figure 2 of the Nature Medicine paper, the Respondent falsified flow cytometry plots as follows: (1) in row 1, the Aire ¥/¥ (thymus) flow cytometry plot [plot 2] and the Aire +/+ ‰ ¥/¥ (thymus) flow cytometry plot [plot 3] are duplicates, thus one of the plots is falsified; (2) in row 2, the Aire ¥/¥ (spleen) flow cytometry plot [plot 2] and the Aire ¥/¥ ‰ +/+ flow cytometry plot [plot 5] are duplicates, thus one of the plots is falsified; (3) in row 3, the Aire ¥/¥ (liver) flow cytometry plot [plot 2] and the Aire +/ + ‰ ¥/¥ (liver) flow cytometry plot [plot 3] are duplicates, thus one of the plots is falsified; and (4) in row 4, the Aire ¥/¥ (thymus) flow cytometry plot [plot 2] and the Aire +/+ ‰ +/+ flow cytometry plot [plot 4] are duplicates, thus one of the plots is falsified. Dr. Deng has entered into a Voluntary Settlement Agreement in which he has voluntarily agreed, for a period of two (2) years, beginning on October 2, 2009: (1) That any institution that submits an application for PHS support for a research project on which the Respondent’s participation is proposed or that uses him in any capacity on PHS-supported research or that submits a report of PHS-funded research in which he is involved must concurrently submit a plan for supervision of his duties to ORI; the supervisory plan must be designed to ensure the integrity of his research contribution; respondent agreed that he will not participate in any PHS-supported research until such a supervisory plan is approved by ORI; (2) That any institution employing him submits, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS funded research in which the Respondent is involved, a certification 1 Mi, Q.-S., Deng, Z.-B., Joshi, S.K., Wang, Z.-Z., Zhou, L., Eckenrode, S., Joshi, R., Ly, D., Yi, B., Delovitch, D.L., & She, J.-X. ‘‘The autoimmune regulator 9Aire) controls iNKT cell development and maturation.’’ Nature Medicine 12:624–626, 2006; hereafter referred to as the ‘‘Nature Medicine paper.’’ PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 to ORI that the data provided by the Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application or report; and (3) To exclude himself from serving in any advisory capacity to the U.S. Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852. (240) 453–8800. John Dahlberg, Director, Division of Investigative Oversight, Office of Research Integrity. [FR Doc. E9–26007 Filed 10–28–09; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): CDC Grants for Public Health Research Dissertation (Panel E), Funding Opportunity Announcement (FOA) PAR07–231, Initial Review In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned SEP: Time and Date: 12 p.m.–3 p.m., December 2, 2009 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters To Be Discussed: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘CDC Grants for Public Health Research Dissertation, FOA PAR07–231, Panel E.’’ Contact Person for More Information: Sheree Marshall Williams, PhD, MSc, Scientific Review Administrator, CDC, 1600 Clifton Road, NE., Mailstop D73, Atlanta, GA 30333, Telephone 404–639–7742. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. E:\FR\FM\29OCN1.SGM 29OCN1

Agencies

[Federal Register Volume 74, Number 208 (Thursday, October 29, 2009)]
[Notices]
[Page 55848]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-26007]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) and the Assistant Secretary for Health have taken final action in 
the following case:
    Zhong Bin Deng, Medical College of Georgia: Based on the report of 
an investigation conducted by the Medical College of Georgia (MCG), the 
report of the MCG Adjudication Subcommittee, additional analysis 
conducted by ORI in its oversight review, and the Respondent's written 
and oral admissions and expressed remorse, ORI found that Dr. Zhong Bin 
Deng, former postdoctoral fellow at MCG in Augusta, GA, engaged in 
scientific misconduct in research supported by National Institute of 
Allergy and Infectious Diseases (NIAID), National Institutes of Health 
(NIH), grant 2 P01 AI42288.
    ORI found that Dr. Deng engaged in scientific/research misconduct 
by falsifying research results reported in a paper published in Nature 
Medicine.\1\ Specifically:
---------------------------------------------------------------------------

    \1\ Mi, Q.-S., Deng, Z.-B., Joshi, S.K., Wang, Z.-Z., Zhou, L., 
Eckenrode, S., Joshi, R., Ly, D., Yi, B., Delovitch, D.L., & She, 
J.-X. ``The autoimmune regulator 9Aire) controls iNKT cell 
development and maturation.'' Nature Medicine 12:624-626, 2006; 
hereafter referred to as the ``Nature Medicine paper.''
---------------------------------------------------------------------------

     Figures 1 and 2 in the Nature Medicine paper purportedly 
show that the autoimmune regulator Arie controls iNKT cell development 
and maturation. In Figure 1(a), the Respondent falsified the Aire +/+ 
(thymus and liver) flow cytometry plots by substituting Aire +/- 
(thymus and liver) flow cytometry plots that were altered to disguise 
their origins and falsified the Aire -/- (bone marrow) flow cytometry 
plot by substituting the Aire +/- (bone marrow) flow cytometry plot, 
also altered to disguise its origin.
     In supplementary Figure 2 of the Nature Medicine paper, 
the Respondent falsified flow cytometry plots as follows: (1) in row 1, 
the Aire -/- (thymus) flow cytometry plot [plot 2] and the Aire +/+ 
>< -/- (thymus) flow 
cytometry plot [plot 3] are duplicates, thus one of the plots is 
falsified; (2) in row 2, the Aire -/- (spleen) flow cytometry plot 
[plot 2] and the Aire -/- >< 
+/+ flow cytometry plot [plot 5] are duplicates, thus one of the plots 
is falsified; (3) in row 3, the Aire -/- (liver) flow cytometry plot 
[plot 2] and the Aire +/+ >< 
-/- (liver) flow cytometry plot [plot 3] are duplicates, thus one of 
the plots is falsified; and (4) in row 4, the Aire -/- (thymus) flow 
cytometry plot [plot 2] and the Aire +/+ 
>< +/+ flow cytometry plot 
[plot 4] are duplicates, thus one of the plots is falsified.
    Dr. Deng has entered into a Voluntary Settlement Agreement in which 
he has voluntarily agreed, for a period of two (2) years, beginning on 
October 2, 2009:
    (1) That any institution that submits an application for PHS 
support for a research project on which the Respondent's participation 
is proposed or that uses him in any capacity on PHS-supported research 
or that submits a report of PHS-funded research in which he is involved 
must concurrently submit a plan for supervision of his duties to ORI; 
the supervisory plan must be designed to ensure the integrity of his 
research contribution; respondent agreed that he will not participate 
in any PHS-supported research until such a supervisory plan is approved 
by ORI;
    (2) That any institution employing him submits, in conjunction with 
each application for PHS funds, or report, manuscript, or abstract 
involving PHS funded research in which the Respondent is involved, a 
certification to ORI that the data provided by the Respondent are based 
on actual experiments or are otherwise legitimately derived and that 
the data, procedures, and methodology are accurately reported in the 
application or report; and
    (3) To exclude himself from serving in any advisory capacity to the 
U.S. Public Health Service (PHS), including but not limited to service 
on any PHS advisory committee, board, and/or peer review committee, or 
as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852. (240) 453-8800.

John Dahlberg,
Director, Division of Investigative Oversight, Office of Research 
Integrity.
[FR Doc. E9-26007 Filed 10-28-09; 8:45 am]
BILLING CODE 4150-31-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.